One stock that might be an intriguing choice for investors right now is Agile Therapeutics, Inc. AGRX. This is because this security in the Medical-Generic Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical-Generic Drugs space as it currently has a Zacks Industry Rank of 32 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Agile Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.
AGILE THERAP Price and Consensus
AGILE THERAP Price and Consensus | AGILE THERAP Quote
In fact, over the past month, current quarter estimates have narrowed from a loss of 30 cents per share to a loss of 29 cents per share, while current year estimates have narrowed from a loss of $1.11 per share to a loss of $1.06 per share. The company currently holds a Zacks Rank #3 (Hold), which is also a favorable signal.
So, if you are looking for a decent pick in a strong industry, consider Agile Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AGILE THERAP (AGRX): Free Stock Analysis Report
To read this article on Zacks.com click here.